|
Real-time
Euronext Bruxelles
07:08:01 2026-09-03 am EDT
|
5-day change | 1st Jan Change | ||
| 219.70 EUR | -0.36% |
|
-0.95% | -7.88% |
| Sep. 01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| Sep. 01 | White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies | MT |
| Market Cap | 42.04B 48.73B 39.6B 36.08B 67.45B 4,603B 67.95B 469B 182B 2,354B 183B 179B 7,732B | P/E 2026 * |
22x | P/E 2027 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 42.35B 49.09B 39.89B 36.35B 67.94B 4,637B 68.45B 472B 183B 2,371B 184B 180B 7,788B | EV / Sales 2026 * |
4.87x | EV / Sales 2027 * | 4.15x |
| Free-Float |
61.59% | Yield 2026 * |
0.66% | Yield 2027 * | 0.68% |
Last Transcript : UCB
| 1 day | -0.32% | ||
| 1 week | -0.95% | ||
| Current month | +2.09% | ||
| 1 month | -0.72% | ||
| 3 months | -12.74% | ||
| 6 months | -13.09% | ||
| Current year | -7.88% |
| 1 week | 214.3 |  | 223.1 |
| 1 month | 211.6 | | 232.9 |
| Current year | 211.6 | | 289.5 |
| 1 year | 191.2 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 2020-06-30 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-12-31 | |
| Director/Board Member | 67 | 2014-12-31 | |
| Director/Board Member | 56 | 2014-04-23 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/15/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.32% | -0.95% | +8.81% | +168.97% | 48.73B | |
| +3.42% | +4.57% | +47.44% | +2.45% | 85.08B | |
| -2.24% | +0.77% | +523.44% | +33.98% | 60.21B | |
| +0.95% | +0.93% | -15.06% | -34.62% | 59.71B | |
| -1.25% | -6.13% | -2.08% | +33.18% | 51.1B | |
| +3.07% | +0.72% | +59.47% | -16.66% | 32.9B | |
| +3.06% | +0.55% | +49.84% | +99.15% | 26.11B | |
| +0.79% | -4.65% | -4.11% | +197.39% | 22.6B | |
| +1.45% | -1.50% | +64.45% | +113.53% | 16.42B | |
| -0.83% | -4.17% | -16.10% | +786.97% | 15.3B | |
| Average | +0.80% | -2.20% | +71.61% | +138.44% | 41.82B | |
| Weighted average by Cap. | +0.81% | -1.54% | +93.15% | +73.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.7B 10.08B 8.2B 7.47B 13.96B 953B 14.06B 97.03B 37.66B 487B 37.87B 37.04B 1,600B | 9.68B 11.23B 9.12B 8.31B 15.54B 1,060B 15.65B 108B 41.91B 542B 42.15B 41.23B 1,781B |
| Net income | 1.93B 2.24B 1.82B 1.66B 3.1B 212B 3.12B 21.56B 8.37B 108B 8.41B 8.23B 355B | 2.33B 2.7B 2.19B 2B 3.73B 255B 3.76B 25.96B 10.07B 130B 10.13B 9.91B 428B |
| Net Debt | 306M 354M 288M 262M 490M 33.45B 494M 3.41B 1.32B 17.1B 1.33B 1.3B 56.19B | -1.81B -2.1B -1.7B -1.55B -2.9B -198B -2.92B -20.16B -7.82B -101B -7.87B -7.7B -332B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-03 | €219.70 | -0.36% | 13,816 |
| 26-09-02 | €220.50 | +0.92% | 202,075 |
| 26-09-01 | €218.50 | +1.49% | 200,601 |
| 26-08-31 | €215.30 | -0.55% | 312,155 |
| 26-08-28 | €216.50 | -2.43% | 257,379 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
